SSKN Strata Skin Sciences

STRATA Skin Sciences to Report Second Quarter 2022 Financial Results on August 10, 2022

STRATA Skin Sciences to Report Second Quarter 2022 Financial Results on August 10, 2022

HORSHAM, Pa., July 27, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2022 financial results on Wednesday, August 10, 2022. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the STRATA Skin Sciences website at:

 under the investor relations section and will be archived for future reference. To listen to the conference call, please dial 1-877-451-6152 (US/Canada), 1-201-389-0879 (International), and use the conference ID number 13730992.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and now the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Investor Contact

Jack Droogan

(203) 585-4140



EN
27/07/2022

Underlying

SSKNStrata Skin Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...

December 9, 2025 1 EN
Free Trial
SSKN Strata Skin Sci...

Strata Skin Sciences Inc: 1 director

A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

SSKN STRATA SKIN SCIENCES
11/19/25 November 19, 2025 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and ...

STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2025, and provides a corporate update. Third Quarter Highlights Continued progress toward historic expansion of CPT codes for reimbursement for inflammator...

November 13, 2025 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes f...

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on...

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thur...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch